ArticleCardiology and therapy2026
Polyneuropathy Assessment and Treatment Patterns in Patients with Hereditary Transthyretin Amyloidosis.
Article in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurologic Stability During Tafamidis Treatment in Transthyretin Amyloidosis with a Mixed Phenotype: A Multicenter Real-World Study.Cardiology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHereditary transthyretin amyloidosis (hATTR) manifests as cardiomyopathy and/or polyneuropathy. Polyneuropathy may be suspected for a variety of reasons, but the clinical evidence supporting that impression varies. We used International Classification of Diseases, Tenth Revision (ICD-10) coding to broadly capture patients thought to have polyneuropathy in a V142I-predominant cohort and examined what clinical documentation actually supported the diagnosis and whether documentation level influences treatment selection.
methodsRetrospective chart review of 54 patients identified by co-occurring ICD-10 codes for transthyretin amyloidosis and polyneuropathy at a major academic medical center, with pathogenic TTR variant confirmation. Polyneuropathy codes were then classified by the level of clinical evidence supporting the diagnosis. Treatment with TTR stabilizers and gene silencers was assessed.
resultsOf 54 patients (90.7% non-Hispanic Black, 87.0% V142I), 51 (94.4%) had confirmed cardiac involvement with 40/42 eligible (95.2%) receiving stabilizers. Sixteen patients (29.6%) received gene silencers, with 11 receiving both concurrently. Clinical evidence supporting the polyneuropathy code was identified in 43 patients (79.6%): ancillary testing confirmation in 18 (33.3%), provider documentation without ancillary testing in 14 (25.9%), and symptoms only in 11 (20.4%). The remaining 11 (20.4%) had insufficient documentation to support the code. Gene silencer use was highest among those with ancillary testing (50.0%) versus symptoms only (18.2%).
conclusionAmong patients with hATTR coded for polyneuropathy, only 33.3% had ancillary testing confirmation. Gene silencer use tracked with documentation quality rather than the presence of a code alone. These findings highlight the gap between administrative coding and clinical documentation and support standardized neurological assessment in hATTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.